Revenue grew 9.4% to $320.2M in fiscal 2026, led by 18% Med Tech growth and margin expansion despite tariffs. Guidance for 2027 calls for 5–6.5% revenue growth, 12–15% Med Tech growth, and continued investment in R&D and clinical data.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.